BOPA 2017 | Targeted medicine for ALK-mutated NSCLC
The rapidly changing landscape of NSCLC treatment has drastically improved outcomes for patients. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP of The Christie NHS Foundation Trust, Manchester, UK discusses targeted medicine for NSCLC patients with ALK gene rearrangements. Dr Summers provides an overview of the impact of the PROFILE 1014 trial (NCT01154140), which tested the efficacy of crizotinib in this patient group. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
Get great new content delivered to your inboxSign up